
Pfizer seen as cautious Buy with 10% annual return but faces patent cliff and dividend risks
Pfizer is considered a cautious Buy, trading near its intrinsic value with an expected 10% annual return mainly from its high dividend yield. However, the company faces significant challenges including a looming patent cliff, a stretched balance shee...



